Ann: Australian Clinical Trials Manager to replace European Role, page-10

100% right @hotcongo. Also super important is getting the key opinion leaders (KOLs) on side and supportive so they suggest the trial to the patients and colleagues. To do this you need to have the right people that the KOLs respect.

The most difficult phase to recruit is Phase I where the correct dosage is not known. The regulatory agencies like the FDA make you start out with a really low dose of the drug which everyone knows is not going to do anything even if the drug works at higher doses. With Bisantrene we have a massive advantage in that we know what cancers it works on and we know the dosage to use. This means we can offer the patients something that has a real chance of working for them rather than a treatment we know will almost certainly do nothing. This is vastly more attractive to a patient.